Autolus Enterprise Value over EBIT from 2010 to 2024
| AUTL Stock | USD 4.21 0.27 6.03% |
Check Autolus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Autolus main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 7.2 M or Total Revenue of 281.2 K, as well as many exotic indicators such as Price To Sales Ratio of 436, Dividend Yield of 0.0 or PTB Ratio of 10.55. Autolus financial statements analysis is a perfect complement when working with Autolus Therapeutics Valuation or Volatility modules.
Autolus | Enterprise Value over EBIT |
About Autolus Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Autolus Therapeutics income statement, its balance sheet, and the statement of cash flows. Autolus Therapeutics investors use historical funamental indicators, such as Autolus Therapeutics's Enterprise Value over EBIT, to determine how well the company is positioned to perform in the future. Although Autolus Therapeutics investors may use each financial statement separately, they are all related. The changes in Autolus Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Autolus Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Autolus Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Autolus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. Autolus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 324 people.
Pair Trading with Autolus Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Autolus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Autolus Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Autolus Stock
| 0.67 | ELYM | Eliem Therapeutics | PairCorr |
| 0.58 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.51 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.47 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.41 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Autolus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Autolus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Autolus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Autolus Therapeutics to buy it.
The correlation of Autolus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Autolus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Autolus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Autolus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Autolus Therapeutics Correlation against competitors. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Autolus Stock analysis
When running Autolus Therapeutics' price analysis, check to measure Autolus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Autolus Therapeutics is operating at the current time. Most of Autolus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Autolus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Autolus Therapeutics' price. Additionally, you may evaluate how the addition of Autolus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Autolus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.20) | Revenue Per Share 0.01 | Quarterly Revenue Growth (1.00) | Return On Assets (0.25) | Return On Equity (1.02) |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.